AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29952699 — intervention group
Group type: EXPERIMENTAL
Intervention: SLOW-FR (slow-velocity foam rolling)
Number of subjects: 17
Study 29952699 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive)
Number of subjects: 17
Study 28857839 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous walking (30 min in the morning)
Number of subjects: 12
Study 28857839 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple short bouts of walking (twenty 90-s bouts over 8 h)
Number of subjects: 12
Study 28857839 — intervention group
Group type: COMPARATOR
Intervention: Control (sitting in a chair for 8 h)
Number of subjects: 12
Study 25363221 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 62
Study 25363221 — intervention group
Group type: COMPARATOR
Intervention: TBNA
Number of subjects: 62
Study 25363221 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA (Group A)
Number of subjects: 62
Study 25363221 — intervention group
Group type: COMPARATOR
Intervention: TBNA (Group A)
Number of subjects: 62
Study 25363221 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA (greater than 15 mm)
Number of subjects: 62
Study 25363221 — intervention group
Group type: COMPARATOR
Intervention: TBNA (greater than 15 mm)
Number of subjects: 62
Study 22773670 — intervention group
Group type: COMPARATOR
Intervention: Enamel prophylaxis (Control)
Number of subjects: 50
Study 22773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched with 35% phosphoric acid for 15 seconds (Group II)
Number of subjects: 50
Study 22773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Etched with 35% phosphoric acid for 60 seconds (Group III)
Number of subjects: 50
Study 22773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned with Prompt L‐pop self‐etching primer (Group IV)
Number of subjects: 50
Study 22773670 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned with Xeno III self‐etching primer (Group V)
Number of subjects: 50
Study 19389083 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidafenacin (0.1 mg twice daily)
Number of subjects: 781
Study 19389083 — intervention group
Group type: COMPARATOR
Intervention: Propiverine (20 mg once daily)
Number of subjects: 781
Study 19389083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 781
Study 17617116 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stent (Group 1)
Number of subjects: 80
Study 17617116 — intervention group
Group type: COMPARATOR
Intervention: Uncovered prosthesis (Group 2)
Number of subjects: 80
Study 14754977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg twice daily via metered-dose inhaler and Babyhaler spacer device
Number of subjects: 625
Study 14754977 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG) 5 mg 4 times daily via metered-dose inhaler and Nebuhaler spacer device
Number of subjects: 625
Study 14754977 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 625
Study 14754977 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 625
Study 11165331 — intervention group
Group type: EXPERIMENTAL
Intervention: Head orientation cue (tilting head towards right or left shoulder based on gain)
Number of subjects: 0
Study 11165331 — intervention group
Group type: EXPERIMENTAL
Intervention: Target orientation cue (rotating home and target positions based on gain)
Number of subjects: 0
Study 11165331 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm posture cue (changing elbow angle from full flexion to full extension based on gain)
Number of subjects: 0
Study 9924241 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1
Number of subjects: 30
Study 9924241 — intervention group
Group type: COMPARATOR
Intervention: saline (control group)
Number of subjects: 30
Study 8154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 1 (2‐3 days after injury)
Number of subjects: 55
Study 8154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II (4‐17 days after injury)
Number of subjects: 55
Study 8154289 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III (4‐45 days after injury)
Number of subjects: 55
Study 8154289 — intervention group
Group type: COMPARATOR
Intervention: Control group (cadaver knees)
Number of subjects: 55
Study 3278955 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 30 mg daily
Number of subjects: 176
Study 3278955 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1 g daily
Number of subjects: 176
Study 29492863 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD-diclofenac
Number of subjects: 1289
Study 29492863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1289
Study 27556830 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based care for CHD
Number of subjects: 5
Study 25708452 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + prednisone
Number of subjects: 0
Study 25708452 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 0
Study 23015537 — intervention group
Group type: EXPERIMENTAL
Intervention: Identity Intervention Programme (IIP)
Number of subjects: 69
Study 23015537 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SPI)
Number of subjects: 69
Study 19861577 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline CTC (three or more CTC per 7.5 ml of blood)
Number of subjects: 467
Study 19861577 — intervention group
Group type: EXPERIMENTAL
Intervention: High CTC at baseline
Number of subjects: 467
Study 19861577 — intervention group
Group type: EXPERIMENTAL
Intervention: High CTC at 1-2 weeks after the start of treatment
Number of subjects: 467
Study 19861577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of CTC and CT imaging
Number of subjects: 467
Study 18594417 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin administration
Number of subjects: 360
Study 18594417 — intervention group
Group type: COMPARATOR
Intervention: High-risk patients (scoring greater than four risk factors)
Number of subjects: 360
Study 18594417 — intervention group
Group type: COMPARATOR
Intervention: Body mass index greater than 30 and hormone therapy use
Number of subjects: 360
Study 16837435 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral formulas
Number of subjects: 10
Study 16837435 — intervention group
Group type: COMPARATOR
Intervention: Standard enteral formulas
Number of subjects: 10
Study 15017493 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 150 mg
Number of subjects: 60
Study 15017493 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 20 mg
Number of subjects: 60
Study 15017493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10744931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure suction drainage (Exudrain)
Number of subjects: 69
Study 10744931 — intervention group
Group type: COMPARATOR
Intervention: High pressure suction drainage (Redivac)
Number of subjects: 69
Study 10744931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 8862936 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg i.v. on day 1 followed by 7 days oral treatment with one 15 mg tablet daily
Number of subjects: 183
Study 8862936 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg i.m. on day 1 followed by 7 days treatment with one 100 mg slow release tablet daily
Number of subjects: 183
Study 1442760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel patch (10% lidocaine base with 3% glycyrrhetinic acid) applied for 60 minutes
Number of subjects: 16
Study 1442760 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel patch (without lidocaine)
Number of subjects: 16
Study 1442760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine gel patch
Number of subjects: 16
Study 3899624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine at doses of 0, 10, 15, 20, and 25 mg daily
Number of subjects: 47
Study 3899624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine at doses of 15-20 mg daily
Number of subjects: 47
Study 3899624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 47
Study 30587335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 80
Study 30587335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization or intravenous antibiotics
Number of subjects: 80
Study 30587335 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PEx recovery
Number of subjects: 80
Study 30587335 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Functioning and Vitality
Number of subjects: 80
Study 28657111 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic couple therapy (5 sessions)
Number of subjects: 43
Study 28657111 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 43
Study 28657111 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOS scale
Number of subjects: 43
Study 28657111 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOS in Study 2
Number of subjects: 43
Study 25991692 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate 500 mg, three times daily for 12 weeks
Number of subjects: 351
Study 25991692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 23612890 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention for oral health self-care practices
Number of subjects: 284
Study 22432232 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw usage for 2 days after surgery
Number of subjects: 60
Study 22432232 — intervention group
Group type: COMPARATOR
Intervention: No straw usage for 2 days after surgery
Number of subjects: 60
Study 20051836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin (2,000 U per catheter line)
Number of subjects: 42
Study 20051836 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) (5,000 U per catheter line)
Number of subjects: 42
Study 17913003 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Whitestrips bleaching gels (5.3% and 6.5% hydrogen peroxide)
Number of subjects: 0
Study 17913003 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gels (no hydrogen peroxide)
Number of subjects: 0
Study 17913003 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 16220234 — intervention group
Group type: EXPERIMENTAL
Intervention: Character education program (school-based and curriculum driven)
Number of subjects: 303
Study 16220234 — intervention group
Group type: COMPARATOR
Intervention: No treatment control condition
Number of subjects: 303
Study 11872367 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone group
Number of subjects: 55
Study 11872367 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 10193952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2 on Day 1) and Etoposide (100 mg/m2 on Days 1, 3, and 5 or Days 4, 6, and 8 every 3 weeks)
Number of subjects: 107
Study 10193952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Etoposide
Number of subjects: 107
Study 7852684 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 45
Study 7852684 — intervention group
Group type: COMPARATOR
Intervention: Lactovegetarians
Number of subjects: 45
Study 2322495 — intervention group
Group type: EXPERIMENTAL
Intervention: High nickel diet (supplementary for 4 days)
Number of subjects: 12
Study 229146 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam hydrochloride (15 mg)
Number of subjects: 6
Study 229146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30980771 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation procedure using collagenated bovine bone mineral and a resorbable collagen membrane
Number of subjects: 40
Study 30980771 — intervention group
Group type: COMPARATOR
Intervention: No grafting (control)
Number of subjects: 40
Study 28706955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast B1 (milk and cereals)
Number of subjects: 12
Study 28706955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast B2 (milk, apple, and chocolate cream‐filled sponge cake)
Number of subjects: 12
Study 28706955 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast B3 (milk, apple, bread, and hazelnut chocolate cream)
Number of subjects: 12
Study 28706955 — intervention group
Group type: EXPERIMENTAL
Intervention: All breakfasts (B1, B2, B3)
Number of subjects: 12
Study 28706955 — intervention group
Group type: COMPARATOR
Intervention: Control A (50 g OGTT)
Number of subjects: 12
Study 25861028 — intervention group
Group type: EXPERIMENTAL
Intervention: Sine wave tracking (45 trials)
Number of subjects: 0
Study 25861028 — intervention group
Group type: COMPARATOR
Intervention: Typical Fitts task (ID = 6) (45 trials)
Number of subjects: 0
Study 23984352 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy plus EMT with a resistive load of 30 cm H2O
Number of subjects: 60
Study 23984352 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy plus EMT with a sham load
Number of subjects: 60
Study 20189663 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (11 weeks)
Number of subjects: 37
Study 20189663 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 37
Study 20189663 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 37
Study 19468716 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 36
Study 19468716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16505423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 77
Study 14764220 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 12
Study 14764220 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 12
Study 11243489 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg/70 kg)
Number of subjects: 18
Study 11243489 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.6 mg/70 kg)
Number of subjects: 18
Study 11243489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9302888 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio guidance system
Number of subjects: 0
Study 9302888 — intervention group
Group type: COMPARATOR
Intervention: Paper map
Number of subjects: 0
Study 9302888 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up turn-by-turn display
Number of subjects: 0
Study 9302888 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down electronic map
Number of subjects: 0
Study 9302888 — intervention group
Group type: COMPARATOR
Intervention: Head-down turn-by-turn display
Number of subjects: 0
Study 8111818 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 102
Study 8111818 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide with menthol
Number of subjects: 102
Study 8111818 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 102
Study 8111818 — intervention group
Group type: COMPARATOR
Intervention: Flunisolide without menthol
Number of subjects: 102
Study 3488532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (600 mg, five times a day for ten days)
Number of subjects: 71
Study 3488532 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 71
Study 3488532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31781605 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about diabetes
Number of subjects: 527
Study 31781605 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk perception for developing diabetes
Number of subjects: 527
Study 31781605 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 527
Study 30037498 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant concurrent chemo-radiotherapy (CCRT)
Number of subjects: 1633
Study 30037498 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (CA)
Number of subjects: 1633
Study 27504605 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 714
Study 27504605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 25310116 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based peer support
Number of subjects: 0
Study 25310116 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer support
Number of subjects: 0
Study 25310116 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 22459311 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy intake (four serves/day)
Number of subjects: 38
Study 22459311 — intervention group
Group type: COMPARATOR
Intervention: Low dairy intake (one serve/day)
Number of subjects: 38
Study 19422657 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training
Number of subjects: 26
Study 19422657 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 26
Study 18343277 — intervention group
Group type: EXPERIMENTAL
Intervention: Certo-lizumab pegol
Number of subjects: 662
Study 15842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic scaler
Number of subjects: 74
Study 15842271 — intervention group
Group type: COMPARATOR
Intervention: Piezoceramic ultrasonic scaler
Number of subjects: 74
Study 12452227 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5 per cent bupivacaine
Number of subjects: 80
Study 12452227 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 10077358 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Testosterone TTS type 1
Number of subjects: 6
Study 10077358 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Testosterone TTS type 1
Number of subjects: 6
Study 10077358 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose Testosterone TTS type 2
Number of subjects: 6
Study 10077358 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 6
Study 7559090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance alone (Regimen I)
Number of subjects: 200
Study 7559090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary guidance plus eating wheat bran biscuits (Regimen II)
Number of subjects: 200
Study 2149492 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (6 mg/kg every 24 h intravenously)
Number of subjects: 50
Study 2149492 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (15 mg/kg every 12 h intravenously)
Number of subjects: 50
Study 2149492 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 50
Study 2149492 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 50
Study 6112931 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131 (5 mg)
Number of subjects: 10
Study 6112931 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 10
Study 6112931 — intervention group
Group type: EXPERIMENTAL
Intervention: DSCG (40 mg)
Number of subjects: 10
Study 31168938 — intervention group
Group type: EXPERIMENTAL
Intervention: BP + DU therapy
Number of subjects: 54
Study 30455246 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg/kg of body weight bezlotoxumab
Number of subjects: 1587
Study 27282077 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP)
Number of subjects: 18
Study 27282077 — intervention group
Group type: COMPARATOR
Intervention: Current Usual Practice Approach (CUPA)
Number of subjects: 18
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training for 6 weeks
Number of subjects: 43
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training for 6 weeks
Number of subjects: 43
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed training for 6 weeks
Number of subjects: 43
Study 25429550 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 43
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: All training groups (aerobic, resistance, mixed)
Number of subjects: 43
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-training values
Number of subjects: 43
Study 25429550 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC values 3 weeks after training
Number of subjects: 43
Study 23328954 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy
Number of subjects: 46
Study 23328954 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib therapy
Number of subjects: 46
Study 23328954 — intervention group
Group type: COMPARATOR
Intervention: Initial LSC percentage
Number of subjects: 46
Study 23328954 — intervention group
Group type: COMPARATOR
Intervention: Comparison of LSCs and LPCs at diagnosis
Number of subjects: 46
Study 21159328 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based cognitive behavioral intervention
Number of subjects: 91
Study 21159328 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually based virtual reality exposure
Number of subjects: 91
Study 20076861 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400mg administered orally 60 minutes before surgery
Number of subjects: 60
Study 20076861 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 60 minutes before surgery
Number of subjects: 60
Study 17630037 — intervention group
Group type: COMPARATOR
Intervention: Single-agent fluorouracil (with levofolinate over 48 h every 2 weeks) until failure, then single-agent irinotecan (Control group A)
Number of subjects: 2135
Study 17630037 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil until failure, then combination chemotherapy (Strategy B)
Number of subjects: 2135
Study 17630037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy from the outset (Strategy C)
Number of subjects: 2135
Study 17630037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination strategy including irinotecan (C-ir)
Number of subjects: 2135